Cas:1678-43-9 (2-oxo-1,2-diphenylethyl) 4-methylbenzenesulfonate manufacturer & supplier

Chemical Name:(2-oxo-1,2-diphenylethyl) 4-methylbenzenesulfonate

CAS.NO:1678-43-9

Synonyms:2-Phenyl-2-tosyloxyacetophenone;benzoin p-toluenesulfonate;1-benzoyl-1-phenylmethyl p-toluenesulfonate;2-Phenyl-2-(p-toluenesulfonyloxy)acetophenone;MFCD04038426;O-Tosylbenzoin;α-Benzoylbenzyl p-Toluenesulfonate;p-Toluenesulfonic Acid α-Benzoylbenzyl Ester

Molecular Formula:C₂₁H₁₈O₄S

Molecular Weight:366.43000

HS Code:2914400090

Physical and Chemical Properties:

Melting point:109ºC

Boiling point:546.83ºC at 760 mmHg

Density:1.258g/cm3

Index of Refraction:1.608

PSA:68.82000

Exact Mass:366.09300

LogP:5.40530

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Phenyl-2-tosyloxyacetophenone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,p-Toluenesulfonic Acid α-Benzoylbenzyl Ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,O-Tosylbenzoin Use and application,O-Tosylbenzoin technical grade,usp/ep/jp grade.

Related News: But they’ll be subject to up to 14 days of mandatory quarantine once they’re back in the US. (2-oxo-1,2-diphenylethyl) 4-methylbenzenesulfonate manufacturer Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost. (2-oxo-1,2-diphenylethyl) 4-methylbenzenesulfonate supplier But they’ll be subject to up to 14 days of mandatory quarantine once they’re back in the US. (2-oxo-1,2-diphenylethyl) 4-methylbenzenesulfonate vendor The patient, who arrived from Wuhan, is ��stable and under medical care,�� the ministry said in a statement, adding there is ��no cause for concern�� for the public. (2-oxo-1,2-diphenylethyl) 4-methylbenzenesulfonate factory Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost.